PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms

• Main Authors: Li, X.-L, Zhou, J, Chan, Z.-L, Chooi, J.-Y, Chen, Z.-R, Chng, W.-J
• Other Authors: CANCER SCIENCE INSTITUTE OF SINGAPORE
• Format: Article
• Published: 2020
• Subjects: antineoplastic agent; prima 1 met; protein Noxa; protein p53; PUMA protein; unclassified drug; 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one; quinuclidine derivative; TP53 protein, human; animal experiment; animal model; apoptosis; Article; cancer growth; cancer inhibition; cell migration; cell proliferation; clinical effectiveness; colony formation; colorectal cancer; controlled study; dose response; female; human; human cell; mouse; nonhuman; protein expression; treatment duration; treatment response; upregulation; animal; Caco-2 cell line; Colorectal Neoplasms; disease model; drug effects; drug screening; genetics; HT-29 cell line; metabolism; nonobese diabetic mouse; pathology; SCID mouse; Animals; Caco-2 Cells; Cell Proliferation; Disease Models, Animal; HT29 Cells; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Quinuclidines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/174132
• Institution: National University of Singapore

10.18632/oncotarget.5385